Lord's Mark Industries investor summit transcript: Q2/H1 update and 18-month launch roadmap
Management says Q2 growth came primarily from the medical devices division after 26 additional IVD device manufacturing licences were received.
By ScoutQuest · · 1 min read
- Additional IVD manufacturing licences
- 26 additional IVD medical devices manufacturing licences
- Renewable energy order pipeline
- 3,000-plus crore
- Renalyx stake
- almost 85% stake in Renalyx
- Period
- Q2 and H1 FY27; 19th November, 2026
- Positioning
- Describes itself as a diversified conglomerate running two platforms — IVD/MedTech (dialysis, genomics, diagnostics) and renewable energy — with 35-plus products across 15-plus states
📈 Management said the growth seen in the second quarter came primarily from the medical devices division, helped by 26 additional IVD medical devices manufacturing licences that widened the product range; no revenue, EBITDA or profit figures are printed on these pages.
📌 The company puts its renewable energy order pipeline at 3,000-plus crore, backed by a Maha PSU and government relationships and described as confirmed orders for the next couple of years, alongside 35-plus products, 15-plus states, 700-plus distributors and 200 and more enterprise clients.
🔬 Management states that commercial shipments of the Renalyx RXT 21 dialysis machine begin in December, with sickle cell screening and UK sales from January 2027, CAR-T clinical trials from February 2027 and US sales from March 2027 subject to US FDA approval.
🏭 It says a third IVD manufacturing plant is targeted by March 2028 and advanced CAR-T treatment centres by June 2028, supported by CDSCO approvals, CE certification, UK MHRA listing, licences from IIT Bombay and BARC, GMP plants and an almost 85% stake in Renalyx.
Also from Lords Mark Industries
Clarification on inadvertent error in September 2026 half-year results; monitoring committee discontinued
20 Nov 2026
Audio and video recording of 19 November 2026 investor conference call uploaded
19 Nov 2026
H1 FY 2026-27 investor presentation flags ₹3,000+ Cr renewable energy order pipeline
17 Nov 2026
More numbers
- Renewable energy order pipeline3,000-plus crore
- Registered trademarks139
- IVD distributors700-plus
- Products in portfolio35-plus
- States of presence15-plus
- Stake acquired in Renalyxalmost 85%
- Additional IVD medical devices manufacturing licences received26 additional IVD medical devices manufacturing licenses
- Cancer types addressed by CAR-T therapy18 types of cancers
- Order book3,000-plus crore
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.